Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Type 1 Diabetes
Diamyd(R) Phase III Study Approved for Younger Patients in the US
June 24th, 2009
Diamyd Medical reported that the company has received approval from the US Food and Drug Administration (FDA) to include children with type 1 diabetes from 10 years of age in the company's Phase III study with the diabetes vaccine Diamyd(R). Diamyd Medical is conducting two parallel phase III studies, one in Europe and one in the USA, comprising a total of 640 patients. The objective of the studies is to evaluate the ability of the Diamyd(R) vaccine to halt or delay the autoimmune attack on the body's insulin-producing cells, thereby preserving the body's own ability to produce insulin in children and adolescents with recent-onset type 1 diabetes. ...
Source: Vaccine Weekly (2009-06-24)
|
